IL6 and COVID-19: Given the efficacy of inhibiting IL-6 activity in treating acute COVID-19 (54, 55) as well as preclinical studies suggesting rescue of fibrotic disease after bleomycin injury (56–58), we also investigated the utility of IL-6 blockade in our model (Extended data Fig. 13a).